Chairman of the Novo Nordisk Foundation, which owns more than a quarter of Novo Nordisk's shares. Sørensen ran Novo before Lars Fruergaard Jørgensen. After the board ousted Jørgensen in May 2025, Sørensen rebuked the board for being "too slow" to grasp the shifts in the market for weight-loss drugs. Following a purge in October 2025 in which seven board members resigned, Sørensen took over as the drugmaker's chairman.
The three questions of greatest concern are -- 1. Is it attractive? 2. Is it amusing? 3. Does it know its place?